Reocclusion of Recanalized Arteries during Intra-arterial Thrombolysis for Acute Ischemic Stroke

References

1. ↵
   Grotta JC, Welch KM, Fagan SC, et al. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke 2001;32:661–668

   Abstract/FREE Full Text
2. ↵
   Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002;59:862–867

   Abstract/FREE Full Text
3. ↵
   Burgin WS, Alexandrov AV. Deterioration following improvement with tPA therapy: carotid thrombosis and re-occlusion. Neurology 2001;56:568–570

   FREE Full Text
4. ↵
   Qureshi AI, Siddiqui AM, Suri MF, et al. Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery 2002;51:1319–1329

   PubMedWeb of Science
5. ↵
   Qureshi AI, Ali Z, Suri MF, et al. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 2001;49:41–50

   CrossRefPubMedWeb of Science
6. ↵
   Qureshi AI, Suri MF, Shatla AA, et al. Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen. Neurosurgery 2000;47:473–479

   PubMed
7. ↵
   Qureshi AI. New grading system for angiographic evaluation of arterial occlusions and recanalization response to intra-arterial thrombolysis in acute ischemic stroke. Neurosurgery 2002;50:1405–1415

   CrossRefPubMedWeb of Science
8. ↵
   Rankin J. Cerebral vascular accidents in patients over the age of 60: II. prognosis. Scott Med J 1957;2:200–215

   PubMed
9. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604–607

   Abstract/FREE Full Text
10. ↵
    Wolfe CD, Taub NA, Woodrow EJ, Burney PG. Assessment of scales of disability and handicap for stroke patients. Stroke 1991;22:1242–1244

    Abstract/FREE Full Text
11. ↵
    Qureshi AI, Boulos AS, Suri MF, et al. A randomized comparison between intraarterial reteplase and intravenous alteplase in a canine basilar thrombosis model (abstract). 2003 Joint Annual Meeting of the AANS/CNS Section on Cerebrovascular Surgery & American Society of Interventional and Therapeutic Neuroradiology, February 16–19, 2003, Phoenix
12. ↵
    Qureshi AI, Suri MF, Ali Z, et al. Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke: a preliminary feasibility and safety study in a non-human primate model [abstr]. 2003 Joint Annual Meeting of the AANS/CNS Section on Cerebrovascular Surgery & American Society of Interventional and Therapeutic Neuroradiology, February 16–19, 2003, Phoenix, Arizona
13. ↵
    Becker R. Dynamics of coronary thrombolysis and reocclusion. Clin Cardiol 1997;20[suppl 3]:III2–5
14. ↵
    Califf RM. Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. Am Heart J 2000;139:S33–37

    CrossRefPubMed
15. Moser M, Nordt T, Peter K, et al. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase. Circulation 1999;100:1858–1864

    Abstract/FREE Full Text
16. ↵
    Nordt TK, Moser M, Kohler B, et al. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction. Thromb Haemost 1998;80:881–886

    PubMedWeb of Science
17. ↵
    Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999;99:3050–3055

    Abstract/FREE Full Text
18. ↵
    Kleiman NS, Tracy RP, Talley JD, et al. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2000;9:5–12
19. ↵
    del Zoppo GJ. Microvascular responses to cerebral ischemia/inflammation. Ann NY Acad Sci 1997;823:132–147

    PubMedWeb of Science
20. ↵
    Coller BS. Augmentation of thrombolysis with antiplatelet drugs. Coron Artery Dis 1996;6:911–914
21. ↵
    Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999;99:2720–2732

    Abstract/FREE Full Text
22. ↵
    Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000;101:2788–2294

    Abstract/FREE Full Text
23. ↵
    Topol EJ. The GUSTO V Investigators: reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905–1914

    CrossRefPubMedWeb of Science
24. ↵
    Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN. Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: part II. clinical aspects and recommendations. Neurosurgery 2000;46:1360–1375

    CrossRefPubMedWeb of Science
25. ↵
    Ross AM, Molhoek P, Lundergan C, et al. HART II Investigators: randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648–652

    Abstract/FREE Full Text
26. ↵
    Nicolini FA, Lee P, Malycky JL, et al. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrinolysis 1996;7:39–48

    CrossRefPubMed